Partnering to Improve Cancer Care in Low- and Middle-Income Countries
Addressing and overcoming inequities in health care around the world is a top priority for Pfizer. These inequities are most apparent in low- and middle-income countries where, historically, access to effective therapies has been difficult, if not impossible. Through our ongoing collaboration with the IDA Foundation, we’re working to change that and improve access to important cancer treatments.
As part of our commitment to looking beyond our backyard and giving back to where the need is the greatest, Pfizer’s Global Commercial Access Partnerships team is collaborating with the IDA Foundation to reduce the global impact of cancer and expand equitable access to quality medicines across 70 low- and middle-income countries in Africa, Latin America, and Asia.
The goal of this partnership is to provide patients with greater access to innovative and life-impacting treatment options for more than 27 types of cancer – from highly treatable forms of breast, cervical, and prostate cancer to others where these essential therapies have the potential to keep families together for longer.
“Working with IDA Foundation to expand our reach across almost 70 countries is an important step, but this is just the start of our commitment,” said Michelle Akande, Vice President, Global Commercial Access Partnerships at Pfizer. “We know that improving patient outcomes and strengthening health systems transcends access to medicines and vaccines, and we will continue to partner to introduce and scale transformational, holistic approaches to help ensure that everyone has access to quality cancer care – no matter where they live, or what they earn.”
Our partnership with the IDA Foundation builds directly on key successes and learnings from our longstanding work with the American Cancer Society and Clinton Health Access Initiative to expand access to quality cancer treatments in sub-Saharan Africa. We are proud of what can be accomplished through private-public partnerships of this type and how we’re doing our part to achieve equity in care and help patients living with cancer in these countries achieve positive health outcomes.